Durable clinical benefit with exemestane in leptomeningeal metastasis of breast cancer
Tóm tắt
Since most chemotherapy agents do not cross the blood brain barrier, the classical approach for leptomeningeal metastasis (LM) of breast cancer is the administration of cranial intra-ventricular chemotherapy. The roles of hormonal agents like tamoxifen and aromatase inhibitors in LM treatment are not clear. We report the case of a patient with leptomeningeal metastasis from breast cancer with longterm stabilisation using exemestane. Although the ideal therapy for LM remains under dedate, hormonal therapy can contribute towards maintaining the response in some patients with LM and hormonepositive breast cancer.
Tài liệu tham khảo
Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Cancer. 1983; 52:2349–54.
Cho SY, Choi HY: Causes of death and metastatic patterns in patients with mammary cancer. Am J Clin Pathol. 1980;73:232–4.
Yap HY, Yap BS, Tahima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer. 1978;42:283–6.
Boogerd W, Hart AAM, Van der Sande JJ, Engelsman E. Meningeal carcinomatosis in breast cancer: prognostic factors and influence of treatment. Cancer. 1991;67:1685–95.
Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561–9.
Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004; 101:810–6.
Bokstein F, Lossos A, Siegal T. Leptomeningeal metastasis from solid tumors. A comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.
Siegal T, Sandbank U, Gabrizon A, et al. Alteration of bloodbrain-CSF barrier in experimental meningeal carcinomalosis: a morphologic and adriamycin-penetration study. J Neurooncol. 1987;4:233–42.
Chamberlain MC. Leptomeningeal metastasis: a review of evaluation and treatment. J Neuro Oncol. 1998;37:271–84.
Boogerd W, Dorresteijn LDA, Van Der Sande JJ, et al. Response of leptomeningeal metastasis from breast cancer to hormonal therapy. Neurology. 2000;55:117–9.
Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer. 1991;63:641–5.
Hansen SB, Galsgard H, von Eyben FE, Westergaard-Nielsen V, Wolf-Jensen J. Tamoxifen for brain metastases from breast cancer. Ann Neurol. 1986;20:544.
Colomer R, Cosos D, Del Campo JM, Boada M, Rubio D, Salvador L. Brain metastases from breast cancer may respond to endocrine therapy. Breast Cancer Res Treat. 1998;12:83–6.
Carey RW, Davis JM, Zervas NT. Tamoxifen-induced regression of cerebral metastases in breast carcinoma. Cancer Res Rep. 1981;65:793–5.
Ozdogan M, Samur M, Bozcuk HS, et al. Durable remission of leptome ningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol. 2003;33:229–31.